scholarly journals The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome

2020 ◽  
Vol 11 ◽  
Author(s):  
Shenhai Liu ◽  
Zhe Jin ◽  
Yiling Zhang ◽  
ShiKuo Rong ◽  
Wenxin He ◽  
...  
Keyword(s):  
Mouse Model ◽  
Neuronal Apoptosis ◽  
Dravet Syndrome ◽  
Glucagon Like Peptide ◽  
Cognition Dysfunction ◽  
Glucagon Like Peptide 1

Co-Purification of Recombinant Modified Glucagon-Like and Glucose-Dependent Insulinotropic Peptide to Create a Two-Component Drug for the Treatment of Type 2 Diabetes Mellitus and Obesity

2021 ◽  
Vol 37 (6) ◽  
pp. 74-83
Author(s):  
A.Yu. Gorbunova ◽  
E.P. Sannikova ◽  
I.I. Gubaidullin ◽  
O.M. Ignatova ◽  
M.Yu. Kopaeva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Mouse Model ◽  
Specific Activity ◽  
Two Component ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Insulinotropic Peptide

In addition to the previously developed recombinant modified human glucagon-like peptide 1 (rmglp1, Glypin), a recombinant modified human glucose-dependent insulinotropic peptide (RMGIP) has been obtained. A new universal reverse-phase HPLC technique has been proposed allowing quantitative analysis of rmGlp1 and rmGip separately and as part of a two-component preparation. The data show that the design of recombinant human rmGip according to the Glypine formula makes it possible to produce one-component and two-component preparations containing various rmGip and rmGlp1 protein ratios ranging from 1:0 to 20:1, using cell biomass samples mixed in predetermined proportions. Studies of human rmGip activity in a mouse model revealed reduced specific activity and signs of weak antagonistic effects. In this regard, there is a need for further study of human rmGip activity in a mouse model, including the use of alternative mouse or rat rmGip. type 2 diabetes mellitus; two-component drug, glucose-dependent insulinotropic peptide, glucagon-like peptide-1 The work was supported by the Internal Grant from National Research Center Kurchatov Institute.

scholarly journals A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity

Circulation ◽  
2013 ◽  
Vol 127 (1) ◽  
pp. 74-85 ◽  
Author(s):  
Mohammad Hossein Noyan-Ashraf ◽  
Eric Akihiko Shikatani ◽  
Irmgard Schuiki ◽  
Ilya Mukovozov ◽  
Jun Wu ◽  
...  
Keyword(s):  
Mouse Model ◽  
Molecular Pathology ◽  
Cardiac Dysfunction ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Glucagon-Like Peptide-1 Cleavage Product Improves Cognitive Function in a Mouse Model of Down Syndrome

eNeuro ◽  
2019 ◽  
Vol 6 (2) ◽  
pp. ENEURO.0031-19.2019 ◽  
Author(s):  
Stephen M. Day ◽  
Wenzhong Yang ◽  
Xin Wang ◽  
Jennifer E. Stern ◽  
Xueyan Zhou ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Cognitive Function ◽  
Mouse Model ◽  
Cleavage Product ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Glucagon-Like Peptide 1 and Atrial Natriuretic Peptide in a Female Mouse Model of Obstructive Pulmonary Disease

2019 ◽  
Vol 4 (1) ◽  
Author(s):  
Emilie Balk-Møller ◽  
Johanne Agerlin Windeløv ◽  
Berit Svendsen ◽  
Jenna Hunt ◽  
Seyed Mojtaba Ghiasi ◽  
...  
Keyword(s):  
Lung Function ◽  
Mouse Model ◽  
Atrial Natriuretic Peptide ◽  
Lung Disease ◽  
Pulmonary Disease ◽  
Natriuretic Peptide ◽  
Obstructive Pulmonary Disease ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Atrial Natriuretic

Abstract Glucagon-like peptide-1 (GLP-1) is protective in lung disease models but the underlying mechanisms remain elusive. Because the hormone atrial natriuretic peptide (ANP) also has beneficial effects in lung disease, we hypothesized that GLP-1 effects may be mediated by ANP expression. To study this putative link, we used a mouse model of chronic obstructive pulmonary disease (COPD) and assessed lung function by unrestrained whole-body plethysmography. In 1 study, we investigated the role of endogenous GLP-1 by genetic GLP-1 receptor (GLP-1R) knockout (KO) and pharmaceutical blockade of the GLP-1R with the antagonist exendin-9 to -39 (EX-9). In another study the effects of exogenous GLP-1 were assessed. Lastly, we investigated the bronchodilatory properties of ANP and a GLP-1R agonist on isolated bronchial sections from healthy and COPD mice. Lung function did not differ between mice receiving phosphate-buffered saline (PBS) and EX-9 or between GLP-1R KO mice and their wild-type littermates. The COPD mice receiving GLP-1R agonist improved pulmonary function (P < .01) with less inflammation, but no less emphysema compared to PBS-treated mice. Compared with the PBS-treated mice, treatment with GLP-1 agonist increased ANP (nppa) gene expression by 10-fold (P < .01) and decreased endothelin-1 (P < .01), a peptide associated with bronchoconstriction. ANP had moderate bronchodilatory effects in isolated bronchial sections and GLP-1R agonist also showed bronchodilatory properties but less than ANP. Responses to both peptides were significantly increased in COPD mice (P < .05, P < .01). Taken together, our study suggests a link between GLP-1 and ANP in COPD.

Sign in / Sign up

Export Citation Format

Share Document